Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Immunoglobulins (also known as intravenous immunoglobulin, IVIG) are used in certain cases to support or treat staphylococcal (Staph) infections, particularly when these infections are severe, recurrent, or occur in immunocompromised individuals. The rationale is that IVIG preparations contain pooled antibodies from many donors, some of which may target Staphylococcus aureus antigens and toxins, including superantigens like toxic shock syndrome toxin (TSST-1). Clinical evidence supporting the use of immunoglobulins in Staph infections is limited but present. Most support comes from case series, small clinical trials, and observational studies, especially in the context of severe invasive infections such as toxic shock syndrome, sepsis, or necrotizing pneumonia. Some clinical guidelines suggest considering IVIG as adjunctive therapy for toxic shock syndrome caused by Staphylococcus aureus, mainly due to the ability of IVIG to neutralize superantigens. However, large randomized controlled trials are lacking, and systematic reviews (e.g., Cochrane Reviews) have concluded that the evidence is insufficient to make strong recommendations for routine use in all patients. In summary, the use of immunoglobulins in Staph infections is scientifically based, especially for severe toxin-mediated disease, but the overall strength of evidence is moderate (rated 3/5) because high-quality, large-scale trials are lacking. IVIG is not considered standard therapy for uncomplicated Staph infections but can be considered in select, severe cases.

More about Immunoglobulins
More about Staph Infections

Other ingredients used for Staph Infections

Other health conditions supported by Immunoglobulins

Products containing Immunoglobulins